Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) Director Arthur A. Levin sold 40,000 shares of Avidity Biosciences stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $35.07, for a total transaction of $1,402,800.00. Following the completion of the transaction, the director now directly owns […]
Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) CEO Sarah Boyce sold 28,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $27.42, for a total value of $767,760.00. Following the completion of the transaction, the chief executive officer now directly […]
Shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) traded down 4.3% on Tuesday . The stock traded as low as $26.07 and last traded at $26.27. 447,285 shares were traded during mid-day trading, a decline of 60% from the average session volume of 1,124,135 shares. The stock had previously closed at $27.45. Analyst […]
Shares of Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) have been assigned an average recommendation of “Buy” from the six analysts that are currently covering the firm, Marketbeat reports. Six analysts have rated the stock with a buy rating. The average 1-year price objective among brokers that have covered the stock in the last […]
Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) has earned a consensus rating of “Buy” from the six ratings firms that are covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating. The average 1-year price objective among brokers that have covered the stock in the last year is […]